- Bright Minds Biosciences (DRUG) has appointed Eight Capital as the agent for its planned unit offering
- The company is not giving any assurances whether or when the offering may be completed or as to the actual size or terms of the offering
- Bright Minds intends to use the net proceeds of the offering as working capital and for general corporate purposes
- Bright Minds Biosciences Inc. opened trading at $2.80 per share
Bright Minds Biosciences (DRUG) has appointed Eight Capital as the agent in its planned overnight marketed offering of units.
The final terms of the offering will be determined at the time of pricing.
The company is not giving any assurances whether or when the offering may be completed, or as to the actual size or terms of the offering.
The closing of the offering will be subject to certain conditions, including the approval of the Canadian Securities Exchange.
The company intends to grant Eight Capital an over-allotment option.
Net proceeds of the offering will be used as working capital and for general corporate purposes.
Bright Minds is a pre-clinical biosciences company focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain.
Bright Minds Biosciences Inc. opened trading at $2.80 per share.
